Julia M Shifman
Overview
Explore the profile of Julia M Shifman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kordonsky A, Gabay M, Rosinoff A, Avishid R, Flornetin A, Deouell N, et al.
Int J Mol Sci
. 2024 Oct;
25(20).
PMID: 39456880
Ubiquitin (Ub) signals are recognized and decoded into cellular responses by Ub-receptors, proteins that tether the Ub-binding domain(s) (UBDs) with response elements. Typically, UBDs bind mono-Ub in highly dynamic and...
2.
Rotenberg N, Feldman M, Shirian J, Hockla A, Radisky E, Shifman J
J Biol Chem
. 2024 Oct;
300(11):107867.
PMID: 39419285
Matrix metalloproteinases (MMPs) are a family of endopeptidases that degrade extracellular matrix proteins, functioning in various physiological processes such as tissue remodeling, embryogenesis, and morphogenesis. Dysregulation of these enzymes is...
3.
Shirian J, Hockla A, Gleba J, Coban M, Rotenberg N, Strik L, et al.
Biomolecules
. 2024 Sep;
14(9).
PMID: 39334953
Matrix metalloproteinases (MMPs) are significant drivers of many diseases, including cancer, and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous MMP inhibitors and are being...
4.
Ghareeb H, Yi Li C, Shenoy A, Rotenberg N, Shifman J, Katoh T, et al.
Angew Chem Int Ed Engl
. 2024 Aug;
64(8):e202414256.
PMID: 39215490
Matrix metallopeptidase 7 (MMP7) plays a crucial role in cancer metastasis and progression, making it an attractive target for therapeutic development. However, the development of selective MMP7 inhibitors is challenging...
5.
Shirian J, Hockla A, Gleba J, Coban M, Rotenberg N, Strik L, et al.
bioRxiv
. 2024 Jul;
PMID: 38979353
Matrix Metalloproteinases (MMPs) are drivers of many diseases including cancer and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are human proteins that inhibit MMPs and are...
6.
Gurusinghe S, Wu Y, DeGrado W, Shifman J
bioRxiv
. 2024 Jul;
PMID: 38979193
Protein-protein interactions (PPIs) govern virtually all cellular processes. Even a single mutation within PPI can significantly influence overall protein functionality and potentially lead to various types of diseases. To date,...
7.
Gurusinghe S, Shifman J
BMC Bioinformatics
. 2024 Apr;
25(1):172.
PMID: 38689238
Background: Protein-protein interactions (PPIs) are conveyed through binding interfaces or surface patches on proteins that become buried upon binding. Structural and biophysical analysis of many protein-protein interfaces revealed certain unique...
8.
Tomazini A, Shifman J
Oncotarget
. 2023 Jul;
14:672-687.
PMID: 37395750
Ras proteins are small GTPases that regulate cell growth and division. Mutations in Ras genes are associated with many types of cancer, making them attractive targets for cancer therapy. Despite...
9.
Bonadio A, Wenig B, Hockla A, Radisky E, Shifman J
J Mol Biol
. 2023 Apr;
435(13):168095.
PMID: 37068580
Matrix metalloproteinases (MMPs) are key drivers of various diseases, including cancer. Development of probes and drugs capable of selectively inhibiting the individual members of the large MMP family remains a...
10.
Gurusinghe S, Oppenheimer B, Shifman J
Protein Sci
. 2022 Sep;
31(10):e4435.
PMID: 36173158
Proteins interact with each other through binding interfaces that differ greatly in size and physico-chemical properties. Within the binding interface, a few residues called hot spots contribute the majority of...